Braftovi (Encorafenib) Patent Expiration, LOE Window & CMS Spending
Braftovi (Encorafenib) by Pfizer: FDA Orange Book core substance LOE 2030-08-27 (last listed 2033-08-05), 0 AB generics, $162.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N210496 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-08-27 |
| Last Listed Patent or Exclusivity Date | 2033-08-05 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $162.6M |
| 2024 Medicare Part D Spend | $138.1M |
| 2024 Medicaid Spend | $24.5M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 25.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.